maintain fve amgen follow solid first
quarter pipelin catalyst remain track
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research may
estim may
price data apr
rate updat apr
currenc amount express
methodolog valu compani
top line grew first quarter product
sale growth driven acquisit
immunolog drug otezla on-going volum growth
cholesterol drug repatha osteoporosi drug prolia
even biosimilar mvasi kanjinti
support wide moat diversifi biotech non-gaap
earn per share grew thank oper margin
improv percentag point lower manufactur
cost improv gross margin share repurchas
manag re-affirmed revenu non-gaap ep
guidanc full year maintain
biggest headwind quarter continu
biosimilar competit neulasta sale fell
million although comparison partli distort
million order biomed advanc
research develop author first quarter
pandem limit impact
key clinic trial pois read year pivot
trial remain track cardiolog drug omecamtiv
mecarbil asthma drug tezepelumab lung cancer drug
sotorasib expect data later quarter
could expand otezla use mild moder
psoriasi set drug also enter trial
potenti treatment recent
announc partnership adapt bring
antibodi market also encourag although timelin
look behind antibody-develop firm like
regeneron also close watch phase
data sever half-life-extend bispecif
therapi oncolog later year includ bcma-
target three program
regard effect pandem exist
busi highli focus hospit physician-
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
leader biotechnology-bas human therapeut
histor expertis renal diseas cancer supportive-car product
flagship drug includ red blood cell booster epogen aranesp immun
system booster neulasta enbrel inflammatori
diseas introduc first cancer therapeut vectibix
receiv approv bone-strengthen drug prolia/xgeva
acquisit onyx bolster firm therapeut oncolog
portfolio nexavar kyproli recent launch includ repatha
cholesterol-low aimovig migrain
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
continu conced price defend share new
biosimilar entrant highli competit market
administ therapi saw much smaller
rel stock benefit first quarter big
pharma biotech firm benefit pushed-
forward sale pharmaci script
see pandem headwind vari minim
headwind oncolog neulasta kyproli nephrolog
parsabiv epogen signific headwind bone
health osteoporosi drug prolia must administ
doctor offic everi six month lower
second-quart sale expect prolia anticip
delay patient visit maintain similar long-term
growth trajectori minim impact model
also work improv reimburs home
infus find altern infus site prolia new
osteoporosi drug even still launch seem less
like affect patient could prescrib
treatment follow fractur alreadi
doctor care due acut issu
complet review potenti impact
coronaviru drug biotech industri pleas see
report coronaviru caus limit impact
pharma
dive growth trend quarter
repatha sale growth begin acceler price
headwind fade domin
share new prescript regeneron sanofi
praluent end first quarter net price
expect stabl rest expect see
sale growth line demand growth howev
price pressur continu migrain drug aimovig
saw sale growth unit growth biosimilar
saw strong growth sale kanjinti biosimilar
version roch oncolog drug herceptin mvasi
roch oncolog drug avastin roughli third
market go end first quarter
expect growth could slow howev amgen
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
